Free Newsletter
Register for our Free Newsletters
Advanced Composites
Amorphous Metal Structures
Analysis and Simulation
Asbestos and Substitutes
Associations, Research Organisations and Universities
Automation Equipment
Building Materials
Bulk Handling and Storage
CFCs and Substitutes
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

New approach to drug delivery through bioadhesive ophthalmic drug ;INSERT

BTG : 06 October, 2006  (New Product)
BTG, the global technology commercialisation company, today announced it had strengthened its portfolio of ophthalmic technologies with the acquisition of a new drug delivery innovation from the French veterinary pharmaceutical laboratory V
The bioadhesive ophthalmic drug insert technology is made of a composite polymeric material in which the medicinal substance is incorporated and then released over a few days. The technology has been available for use in veterinary practice for more than two years and trials have shown excellent retention characteristics with no toxicity or allergic reaction.

BODI has advantages over existing drug delivery products including:

The inserts dissolve and therefore do not require surgical removal
Good adhesive properties, which means inserts stay in place
The drug delivery mechanism allows accurate dosing over several days as well as multiple drug dosing.

Dr Patrick Bellon, DVM, Corporate Director Business and Expertise Development at Vétoquinol, said: “Patient compliance and therapeutic dose accuracy are major problems for ophthalmic drugs administered by eye drops, and BODI is a major step forward in addressing these issues. We have proven it works in the veterinary sphere and now BTG can find the right development partner to allow humans the chance to benefit as well.”

BTG’s Ophthalmic Portfolio
Part of BTG’s business strategy is to continue to expand its technology offering in the ophthalmic area. “We have identified a number of strong technologies that address unmet medical needs in eye care”, says Antony Odell, Business Manager of BTG’s Medical Devices and Drug Delivery group. “The acquisition of BODI is a good complement to our surgical sealants technology, which is currently in clinical trials for indications in eye surgery.” BTG continues to search for additional technologies that will expand its portfolio within the ophthalmic market.

BTG is now looking for suitable partners with which to develop and manufacture BODI, as well as its surgical sealants.

Product improvements are occurring in many markets, while new therapeutic developments are expanding the glaucoma-related segment. In addition, traditional drug delivery therapies, including eye drops, are yielding to innovations such as implantables, infusion-type products, and oral and slow-release delivery systems. In addition to the technical issues, favourable demographic trends can contribute to the growth of ophthalmic pharmaceuticals.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   Â© 2012
Netgains Logo